Ronny Drapkin

List of Publications by Citations

154 papers	18,082 citations	62 h-index	134 g-index
170 ext. papers	20,726 ext. citations	12.4 avg, IF	6.18 L-index

#	Paper	IF	Citations
154	Dicer-deficient mouse embryonic stem cells are defective in differentiation and centromeric silencing. *Genes and Development*, **2005**, 19, 489-501	12.6	987
153	Rethinking ovarian cancer: recommendations for improving outcomes. *Nature Reviews Cancer*, **2011** , 11, 719-25	31.3	893
152	Whole-genome characterization of chemoresistant ovarian cancer. *Nature*, **2015**, 521, 489-94	50.4	890
151	53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. *Nature Structural and Molecular Biology*, **2010**, 17, 688-95	17.6	707
150	A candidate precursor to serous carcinoma that originates in the distal fallopian tube. *Journal of Pathology*, **2007**, 211, 26-35	9.4	645
149	Dual role of TFIIH in DNA excision repair and in transcription by RNA polymerase II. *Nature*, **1994**, 368, 769-72	50.4	635
148	The ubiquitin ligase activity in the DDB2 and CSA complexes is differentially regulated by the COP9 signalosome in response to DNA damage. *Cell*, **2003**, 113, 357-67	56.2	604
147	Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. *Nature Reviews Cancer*, **2015**, 15, 668-79	31.3	581
146	BACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function. *Cell*, **2001**, 105, 149-60	56.2	520
145	Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. *Science*, **2011**, 334, 1129-33	33.3	417
144	Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. *Cancer Research*, **2005**, 65, 2162-9	10.1	399
143	Cdk-activating kinase complex is a component of human transcription factor TFIIH. *Nature*, **1995**, 374, 283-7	50.4	381
142	Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. *Journal of Clinical Investigation*, **2013**, 123, 517-25	15.9	371
141	Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models. *Cancer Cell*, **2013**, 24, 751-65	24.3	366
140	The distal fallopian tube: a new model for pelvic serous carcinogenesis. *Current Opinion in Obstetrics and Gynecology*, **2007**, 19, 3-9	2.4	361
139	A recurrent mutation in PALB2 in Finnish cancer families. *Nature*, **2007**, 446, 316-9	50.4	349
138	A comprehensive analysis of PAX8 expression in human epithelial tumors. *American Journal of Surgical Pathology*, **2011**, 35, 816-26	6.7	334

137	High grade serous ovarian carcinomas originate in the fallopian tube. *Nature Communications*, **2017**, 8, 1093	17.4	325
136	Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2011**, 108, 12372-7	11.5	321
135	A human RNA polymerase II complex associated with SRB and DNA-repair proteins. *Nature*, **1996**, 381, 86-9	50.4	312
134	New insights into the pathogenesis of serous ovarian cancer and its clinical impact. *Journal of Clinical Oncology*, **2008**, 26, 5284-93	2.2	302
133	The p400 complex is an essential E1A transformation target. *Cell*, **2001**, 106, 297-307	56.2	257
132	BRCA1 supports XIST RNA concentration on the inactive X chromosome. *Cell*, **2002**, 111, 393-405	56.2	255
131	Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer. *Clinical Medicine and Research*, **2007**, 5, 35-44	1.4	250
130	Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy. *Cell*, **2015**, 160, 977-989	56.2	237
129	Serous carcinogenesis in the fallopian tube: a descriptive classification. *International Journal of Gynecological Pathology*, **2008**, 27, 1-9	3.2	230
128	A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. *Gynecologic Oncology*, **2008**, 109, 168-73	4.9	218
127	Modeling high-grade serous ovarian carcinogenesis from the fallopian tube. *Proceedings of the National Academy of Sciences of the United States of America*, **2011**, 108, 7547-52	11.5	209
126	The BRCA1-associated protein BACH1 is a DNA helicase targeted by clinically relevant inactivating mutations. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 2357-62	11.5	190
125	An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. *Cancer Cell*, **2010**, 17, 298-310	24.3	183
124	PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma. *American Journal of Surgical Pathology*, **2010**, 34, 627-35	6.7	177
123	RNA polymerase II stalled at a thymine dimer: footprint and effect on excision repair. *Nucleic Acids Research*, **1997**, 25, 787-93	20.1	159
122	Primary ex vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis. *Oncogene*, **2010**, 29, 1103-13	9.2	156
121	Human cyclin-dependent kinase-activating kinase exists in three distinct complexes. *Proceedings of the National Academy of Sciences of the United States of America*, **1996**, 93, 6488-93	11.5	147
120	Where transcription meets repair. *Cell*, **1994**, 77, 9-12	56.2	146

119	Pathogenesis and heterogeneity of ovarian cancer. *Current Opinion in Obstetrics and Gynecology*, **2017**, 29, 26-34	2.4	135
118	Targeted tumor-penetrating siRNA nanocomplexes for credentialing the ovarian cancer oncogene ID4. *Science Translational Medicine*, **2012**, 4, 147ra112	17.5	135
117	PEPCK Coordinates the Regulation of Central Carbon Metabolism to Promote Cancer Cell Growth. *Molecular Cell*, **2015**, 60, 571-83	17.6	126
116	A molecular signature of gastric metaplasia arising in response to acute parietal cell loss. *Gastroenterology*, **2008**, 134, 511-22	13.3	124
115	Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome. *Clinical Cancer Research*, **2012**, 18, 5806-15	12.9	118
114	An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, 232-7	11.5	112
113	The 62- and 80-kDa subunits of transcription factor IIH mediate the interaction with Epstein-Barr virus nuclear protein 2. *Proceedings of the National Academy of Sciences of the United States of America*, **1995**, 92, 3259-63	11.5	103
112	Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers. *Cancer Research*, **2014**, 74, 1141-52	10.1	102
111	GATA3 Is a Sensitive and Specific Marker of Benign and Malignant Mesonephric Lesions in the Lower Female Genital Tract. *American Journal of Surgical Pathology*, **2015**, 39, 1411-9	6.7	98
110	Primary culture and immortalization of human fallopian tube secretory epithelial cells. *Nature Protocols*, **2012**, 7, 1755-64	18.8	97
109	Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1-Mutant Ovarian Cancer. *Cell Reports*, **2016**, 14, 429-439	10.6	91
108	Regulation of RNA polymerase II transcription. *Current Opinion in Cell Biology*, **1993**, 5, 469-76	9	89
107	Distinctive cytogenetic profile in benign metastasizing leiomyoma: pathogenetic implications. *American Journal of Surgical Pathology*, **2007**, 31, 737-43	6.7	85
106	Angiogenic mRNA and microRNA gene expression signature predicts a novel subtype of serous ovarian cancer. *PLoS ONE*, **2012**, 7, e30269	3.7	84
105	Mesenchymal gene program-expressing ovarian cancer spheroids exhibit enhanced mesothelial clearance. *Journal of Clinical Investigation*, **2014**, 124, 2611-25	15.9	84
104	It's Totally Tubular....Riding The New Wave of Ovarian Cancer Research. *Cancer Research*, **2016**, 76, 10-7	10.1	82
103	Tubal and ovarian pathways to pelvic epithelial cancer: a pathological perspective. *Histopathology*, **2008**, 53, 127-38	7.3	81
102	The multifunctional TFIIH complex and transcriptional control. *Trends in Biochemical Sciences*, **1994**, 19, 504-8	10.3	80

101	Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition. *Clinical Cancer Research*, **2017**, 23, 1862-1874	12.9	78
100	Long Noncoding RNA Ceruloplasmin Promotes Cancer Growth by Altering Glycolysis. *Cell Reports*, **2015**, 13, 2395-2402	10.6	75
99	Purification of human RNA polymerase II and general transcription factors. *Methods in Enzymology*, **1996**, 274, 72-100	1.7	75
98	Correlation of serum HE4 with tumor size and myometrial invasion in endometrial cancer. *Gynecologic Oncology*, **2012**, 124, 270-5	4.9	67
97	Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics. *Clinical Cancer Research*, **2017**, 23, 1263-1273	12.9	67
96	Regression of drug-resistant lung cancer by the combination of rosiglitazone and carboplatin. *Clinical Cancer Research*, **2008**, 14, 6478-86	12.9	67
95	Further evidence for BRCA1 communication with the inactive X chromosome. *Cell*, **2007**, 128, 991-1002	56.2	67
94	Coming into focus: the nonovarian origins of ovarian cancer. *Annals of Oncology*, **2013**, 24 Suppl 8, viii28-viii35	10.3	64
93	Stathmin 1, a marker of PI3K pathway activation and regulator of microtubule dynamics, is expressed in early pelvic serous carcinomas. *Gynecologic Oncology*, **2011**, 123, 5-12	4.9	63
92	Expression of candidate tumor markers in ovarian carcinoma and benign ovary: evidence for a link between epithelial phenotype and neoplasia. *Human Pathology*, **2004**, 35, 1014-21	3.7	61
91	CARM1-expressing ovarian cancer depends on the histone methyltransferase EZH2 activity. *Nature Communications*, **2018**, 9, 631	17.4	55
90	CCNE1 amplification and centrosome number abnormality in serous tubal intraepithelial carcinoma: further evidence supporting its role as a precursor of ovarian high-grade serous carcinoma. *Modern Pathology*, **2016**, 29, 1254-61	9.8	54
89	Beyond genomics: critical evaluation of cell line utility for ovarian cancer research. *Gynecologic Oncology*, **2015**, 139, 97-103	4.9	52
88	A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers. *JCI Insight*, **2017**, 2, e89760	9.9	49
87	Integrated Genomic, Epigenomic, and Expression Analyses of Ovarian Cancer Cell Lines. *Cell Reports* , **2018**, 25, 2617-2633	10.6	49
86	YAP induces high-grade serous carcinoma in fallopian tube secretory epithelial cells. *Oncogene*, **2016**, 35, 2247-65	9.2	46
85	HE4 (WFDC2) Promotes Tumor Growth in Endometrial Cancer Cell Lines. *International Journal of Molecular Sciences*, **2013**, 14, 6026-43	6.3	46
84	Overexpression of elafin in ovarian carcinoma is driven by genomic gains and activation of the nuclear factor kappaB pathway and is associated with poor overall survival. *Neoplasia*, **2010**, 12, 161-72	6.4	46

83	A novel breast cancer-associated BRIP1 (FANCJ/BACH1) germ-line mutation impairs protein stability and function. *Clinical Cancer Research*, **2008**, 14, 4672-80	12.9	46
82	Creation of a Human Secretome: A Novel Composite Library of Human Secreted Proteins: Validation Using Ovarian Cancer Gene Expression Data and a Virtual Secretome Array. *Clinical Cancer Research*, **2015**, 21, 4960-9	12.9	44
81	PRKCI promotes immune suppression in ovarian cancer. *Genes and Development*, **2017**, 31, 1109-1121	12.6	43
80	Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer. *Nature Communications*, **2015**, 6, 8234	17.4	40
79	Tumor-Targeted Synergistic Blockade of MAPK and PI3K from a Layer-by-Layer Nanoparticle. *Clinical Cancer Research*, **2015**, 21, 4410-9	12.9	40
78	Inhibition of the integrin/FAK signaling axis and c-Myc synergistically disrupts ovarian cancer malignancy. *Oncogenesis*, **2017**, 6, e295	6.6	38
77	Combined therapy with thrombospondin-1 type I repeats (3TSR) and chemotherapy induces regression and significantly improves survival in a preclinical model of advanced stage epithelial ovarian cancer. *FASEB Journal*, **2015**, 29, 576-88	0.9	38
76	A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma. *Gynecologic Oncology*, **2018**, 149, 585-591	4.9	38
75	CD151-α3β1 integrin complexes suppress ovarian tumor growth by repressing slug-mediated EMT and canonical Wnt signaling. *Oncotarget*, **2014**, 5, 12203-17	3.3	36
74	In vivo multiplexed interrogation of amplified genes identifies GAB2 as an ovarian cancer oncogene. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 1102-7	11.5	35
73	High throughput interrogation of somatic mutations in high grade serous cancer of the ovary. *PLoS ONE*, **2011**, 6, e24433	3.7	35
72	Stathmin 1 and p16(INK4A) are sensitive adjunct biomarkers for serous tubal intraepithelial carcinoma. *Gynecologic Oncology*, **2015**, 139, 104-11	4.9	34
71	Anti-CCR4 monoclonal antibody enhances antitumor immunity by modulating tumor-infiltrating Tregs in an ovarian cancer xenograft humanized mouse model. *OncoImmunology*, **2016**, 5, e1090075	7.2	34
70	The hormonal composition of follicular fluid and its implications for ovarian cancer pathogenesis. *Reproductive Biology and Endocrinology*, **2014**, 12, 60	5	34
69	Adenofibroma of the fimbria: a common entity that is indistinguishable from ovarian adenofibroma. *International Journal of Gynecological Pathology*, **2008**, 27, 390-7	3.2	34
68	Interrogation of Functional Cell-Surface Markers Identifies CD151 Dependency in High-Grade Serous Ovarian Cancer. *Cell Reports*, **2017**, 18, 2343-2358	10.6	33
67	Systems analysis of apoptotic priming in ovarian cancer identifies vulnerabilities and predictors of drug response. *Nature Communications*, **2017**, 8, 365	17.4	33
66	Cell-type-specific enrichment of risk-associated regulatory elements at ovarian cancer susceptibility loci. *Human Molecular Genetics*, **2015**, 24, 3595-607	5.6	32

65	Elafin drives poor outcome in high-grade serous ovarian cancers and basal-like breast tumors. *Oncogene*, **2015**, 34, 373-83	9.2	31
64	Role of miR-182 in response to oxidative stress in the cell fate of human fallopian tube epithelial cells. *Oncotarget*, **2015**, 6, 38983-98	3.3	31
63	Modeling High-Grade Serous Carcinoma: How Converging Insights into Pathogenesis and Genetics are Driving Better Experimental Platforms. *Frontiers in Oncology*, **2013**, 3, 217	5.3	30
62	Association of BRCA1 with the inactive X chromosome and XIST RNA. *Philosophical Transactions of the Royal Society B: Biological Sciences*, **2004**, 359, 123-8	5.8	30
61	Human epididymis protein 4 is up-regulated in gastric and pancreatic adenocarcinomas. *Human Pathology*, **2013**, 44, 734-42	3.7	29
60	GATA3 expression in gestational trophoblastic tissues and tumours. *Histopathology*, **2015**, 67, 636-44	7.3	28
59	Mutant p53 regulates ovarian cancer transformed phenotypes through autocrine matrix deposition. *JCI Insight*, **2016**, 1,	9.9	28
58	Epigenetic remodeling regulates transcriptional changes between ovarian cancer and benign precursors. *JCI Insight*, **2016**, 1,	9.9	28
57	Combined MEK and BCL-2/X Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient-Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness. *Molecular Cancer Therapeutics*, **2019**, 18, 642-655	6.1	26
56	Use of yeast-secreted in vivo biotinylated recombinant antibodies (Biobodies) in bead-based ELISA. *Clinical Cancer Research*, **2008**, 14, 2647-55	12.9	26
55	Development of a prosaposin-derived therapeutic cyclic peptide that targets ovarian cancer via the tumor microenvironment. *Science Translational Medicine*, **2016**, 8, 329ra34	17.5	25
54	Early Loss of Histone H2B Monoubiquitylation Alters Chromatin Accessibility and Activates Key Immune Pathways That Facilitate Progression of Ovarian Cancer. *Cancer Research*, **2019**, 79, 760-772	10.1	25
53	Innervation of cervical carcinoma is mediated by cancer-derived exosomes. *Gynecologic Oncology*, **2019**, 154, 228-235	4.9	24
52	Tubal and ovarian pathways to pelvic epithelial cancer: a pathological perspective. *Histopathology*, **2009**, 55, 619	7.3	24
51	Immunoaffinity purification of the human multisubunit transcription factor IIH. *Journal of Biological Chemistry*, **1998**, 273, 7134-40	5.4	24
50	Endosalpingiosis as it relates to tubal, ovarian and serous neoplastic tissues: an immunohistochemical study of tubal and Müllerian antigens. *Gynecologic Oncology*, **2014**, 132, 316-21	4.9	23
49	Promoter methylation of the SALL2 tumor suppressor gene in ovarian cancers. *Molecular Oncology*, **2013**, 7, 419-27	7.9	23
48	Stathmin-1 expression as a complement to p16 helps identify high-grade cervical intraepithelial neoplasia with increased specificity. *American Journal of Surgical Pathology*, **2013**, 37, 89-97	6.7	23

47	Aberrant expression of the dendritic cell marker TNFAIP2 by the malignant cells of Hodgkin lymphoma and primary mediastinal large B-cell lymphoma distinguishes these tumor types from morphologically and phenotypically similar lymphomas. *American Journal of Surgical Pathology*, **2011**, 35, 1531-9	6.7	23
46	Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference. *Cancer*, **2019**, 125, 1963-1972	6.4	22
45	Use of CA125 and HE4 serum markers to predict ovarian cancer in elevated-risk women. *Cancer Epidemiology Biomarkers and Prevention*, **2014**, 23, 1383-93	4	22
44	FOXO3a loss is a frequent early event in high-grade pelvic serous carcinogenesis. *Oncogene*, **2014**, 33, 4424-32	9.2	21
43	HE4 transcription- and splice variants-specific expression in endometrial cancer and correlation with patient survival. *International Journal of Molecular Sciences*, **2013**, 14, 22655-77	6.3	20
42	Precious GEMMs: emergence of faithful models for ovarian cancer research. *Journal of Pathology*, **2018**, 245, 129-131	9.4	19
41	CLIC1 and CLIC4 complement CA125 as a diagnostic biomarker panel for all subtypes of epithelial ovarian cancer. *Scientific Reports*, **2018**, 8, 14725	4.9	19
40	Ex vivo culture of primary human fallopian tube epithelial cells. *Journal of Visualized Experiments*, **2011**,	1.6	16
39	In vivo modeling of metastatic human high-grade serous ovarian cancer in mice. *PLoS Genetics*, **2020**, 16, e1008808	6	15
38	SUSD2 expression in high-grade serous ovarian cancer correlates with increased patient survival and defective mesothelial clearance. *Oncogenesis*, **2016**, 5, e264	6.6	15
37	The polyoma virus large T binding protein p150 is a transcriptional repressor of c-MYC. *PLoS ONE*, **2012**, 7, e46486	3.7	15
36	Primordial germ cells as a potential shared cell of origin for mucinous cystic neoplasms of the pancreas and mucinous ovarian tumors. *Journal of Pathology*, **2018**, 246, 459-469	9.4	15
35	Prior appendectomy does not protect against subsequent development of malignant or borderline mucinous ovarian neoplasms. *Gynecologic Oncology*, **2014**, 132, 328-33	4.9	14
34	The new face of ovarian cancer modeling: better prospects for detection and treatment. *F1000 Medicine Reports*, **2011**, 3, 22		14
33	Tumor Innervation: Cancer Has Some Nerve. *Trends in Cancer*, **2020**, 6, 1059-1067	12.5	14
32	Expression of the POTE gene family in human ovarian cancer. *Scientific Reports*, **2018**, 8, 17136	4.9	13
31	Inactivation of Arid1a in the endometrium is associated with endometrioid tumorigenesis through transcriptional reprogramming. *Nature Communications*, **2020**, 11, 2717	17.4	12
30	Testing ovarian cancer cell lines to train dogs to detect ovarian cancer from blood plasma: A pilot study. *Journal of Veterinary Behavior: Clinical Applications and Research*, **2019**, 32, 42-48	1.9	11

29	miR-181a initiates and perpetuates oncogenic transformation through the regulation of innate immune signaling. *Nature Communications*, **2020**, 11, 3231	17.4	11
28	Tumor innervation: peripheral nerves take control of the tumor microenvironment. *Journal of Clinical Investigation*, **2021**, 131,	15.9	11
27	Chromosomal Instability and mTORC1 Activation through PTEN Loss Contribute to Proteotoxic Stress in Ovarian Carcinoma. *Cancer Research*, **2019**, 79, 5536-5549	10.1	9
26	CD105 Is Expressed in Ovarian Cancer Precursor Lesions and Is Required for Metastasis to the Ovary. *Cancers*, **2019**, 11,	6.6	9
25	Does the fimbria have an embryologic origin distinct from that of the rest of the fallopian tube?. *Fertility and Sterility*, **2008**, 90, 2008.e5-8	4.8	9
24	TGFBI Production by Macrophages Contributes to an Immunosuppressive Microenvironment in Ovarian Cancer. *Cancer Research*, **2021**, 81, 5706-5719	10.1	9
23	Unilateral transverse arm defect with subterminal digital nubbins. *Pediatric and Developmental Pathology*, **2003**, 6, 348-54	2.2	8
22	Ovarian granulosa cell tumor characterization identifies FOXL2 as an immunotherapeutic target. *JCI Insight*, **2020**, 5,	9.9	7
21	The tubal epigenome - An emerging target for ovarian cancer. *Pharmacology & Therapeutics*, **2020**, 210, 107524	13.9	6
20	Rationale for Developing a Specimen Bank to Study the Pathogenesis of High-Grade Serous Carcinoma: A Review of the Evidence. *Cancer Prevention Research*, **2016**, 9, 713-20	3.2	6
19	Urokinase-type plasminogen activator receptor: a beacon of malignancy?. *Clinical Cancer Research*, **2008**, 14, 5643-5	12.9	6
18	Targeting glutamine dependence through GLS1 inhibition suppresses ARID1A-inactivated clear cell ovarian carcinoma. *Nature Cancer*, **2021**, 2, 189-200	15.4	6
17	Unraveling the Mysteries of PAX8 in Reproductive Tract Cancers. *Cancer Research*, **2021**, 81, 806-810	10.1	5
16	A candidate precursor to serous carcinoma that originates in the distal fallopian tube (J Pathol 2007; 211: 26□5). *Journal of Pathology*, **2007**, 213, 116-116	9.4	4
15	Predicting master transcription factors from pan-cancer expression data		4
14	Tumor-infiltrating nerves create an electro-physiologically active microenvironment and contribute to treatment resistance		4
13	An Activated ErbB3/NRG1 Autocrine Loop Supports In Vivo Proliferation in Ovarian Cancer Cells. *Cancer Cell*, **2010**, 17, 412	24.3	3
12	Fallopian tube precursor lesions of serous ovarian carcinoma require L1CAM for dissemination and metastasis		3

11	Deubiquitinase UCHL1 Maintains Protein Homeostasis through the PSMA7-APEH-Proteasome Axis in High-grade Serous Ovarian Carcinoma. *Molecular Cancer Research*, **2021**, 19, 1168-1181	6.6	3
10	Predicting master transcription factors from pan-cancer expression data. *Science Advances*, **2021**, 7, eabf6133	14.3	2
9	The SETDB1-TRIM28 Complex Suppresses Antitumor Immunity. *Cancer Immunology Research*, **2021**, 9, 1413-1424	12.5	2
8	DNA Methylation Profiles of Ovarian Clear Cell Carcinoma. *Cancer Epidemiology Biomarkers and Prevention*, **2021**,	4	2
7	PAX8 orchestrates an angiogenic program through interaction with SOX17		2
6	Cell Fitness: More Than Push-Ups. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	2
5	There is a need for routine peritoneal cytology at RRSO. *Gynecologic Oncology*, **2013**, 128, 149-150	4.9	1
4	Cancers Arising in the Ovary **2014**, 1592-1613.e6		1
3	Elafin: a double agent in breast and ovarian cancer. *Oncoscience*, **2015**, 2, 793-4	0.8	0
2	Flower lose, a cell fitness marker, predicts COVID-19 prognosis. *EMBO Molecular Medicine*, **2021**, 13, e13714	11	0
1	The transcription factor PAX8 promotes angiogenesis in ovarian cancer through interaction with SOX17.. *Science Signaling*, **2022**, 15, eabm2496	8.8	0